DMF ‘significantly reduces disability progression’

[MSUK]

Delayed-release dimethyl fumarate (DMF) has been associated with significant reductions in confirmed disability progression (CDP) in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS), compared with placebo, presented J. Theodore Phillips, MD, PhD, FAAN, Baylor Institute for Immunology Research, Dallas, TX, at the 68th American Academy of Neurology meeting in Vancouver, Canada...Read more - http://www.ms-uk.org/MSnews